CompletedNot Applicable

Impact of Different Lung Isolation Devices on Pharyngolaryngeal Injuries After Pulmonary Resection

China270 participantsStarted 2025-08-18

Plain-language summary

The goal of this clinical trial is to assess the impact of laryngeal mask combined with visual bronchial blocker on pharyngolaryngeal injury after pulmonary resection in patients with pulmonary nodules. The main question it aims to answer is: the incidence of postoperative pharyngolaryngeal injury within 24h : sore throat and hoarseness ? Researchers will compare the visual bronchial blocker group (VBB) with the double-lumen endotracheal tube group (DLT) to see if the visual bronchial blocker group can minimize laryngopharyngeal injury after pulmonary resection.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Scheduled for elective VATS pulmonary resection under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) 18.5-30.0 kg/m² * Written informed consent Exclusion Criteria: * Anticipated difficult airway (Mallampati class IV, previous difficult intubation, airway abnormalities) * Gastroesophageal reflux disease or gastric retention * Active pulmonary infection or bleeding * Severe pulmonary dysfunction (FEV1 \<50% predicted) * Previous lung surgery or bilateral lung surgery * Cognitive impairment affecting outcome assessment * Chronic throat pain or voice abnormalities within 24 hours preoperatively * Abnormal right upper lobe bronchial anatomy on preoperative CT for right-sided procedures * Any condition deemed unsuitable for study participation by anesthesiologist or surgeon

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of pharyngolaryngeal injuries within postoperative 24 hours

Timeframe: within postoperative 24 hours

Trial details

NCT IDNCT07117539

SponsorTingting Li

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-31

View on ClinicalTrials.gov More Pulmonary Neoplasm trials